ASC TECHNOLOGYNext Generation
Antigen Delivery

https://vaccizone.com/wp-content/uploads/2020/06/home_hero_detail.jpg

WHAT ARE WE WORKING ON?

Vaccizone is developing next generation antigen delivery and vaccine technologies for human and animal diseases based on its novel ASC technology. We are building a platform that changes the vaccine and treatment development paradigm for preventable diseases.

ASC TECHNOLOGY

VacciZone has developed and patented a novel method for an antigen/bioactive delivery which increases both the antigenicity of the antigen as well as enhancing its stability at high temperatures, freeze thaw cycles and organic solvents.

What is special about the ASC Technology?

Delivery of antigens to Antigen Presenting Cells (APCs) is enhanced
Degradation of antigens after endocytosis or phagocytosis is decreased
Size of antigens is increased to facilitate engulfment by APCs
Antigen is stable at 37°C for >30 days
Antigen can endure >8 freeze-thaw cycles without degradation
ASC speck is a modified inflammasome complex so it can also function as an adjuvant

Our Technology

SUMMARYPIPELINE

VacciZone has three ongoing projects on COVID-19, Melanoma & Veterinary vaccines with patented next generation antigen delivery technology for immunotherapy.

CEO & CSOProf. Dr. Nesrin Özören

Prof. Nesrin Özören from Boğaziçi University (Ph.D. in molecular biology from UPENN) is the inventor of the ASC speck delivery technology, has won multiple awards and grants and is the current president of the Turkish Molecular Biology Association. Prof. Özören has secured multiple project and grant money during her experience as a leader of an independent laboratory for the last 15 years.

EMAİL

nesrin.ozoren@vaccizone.com